Prescribing Medical Marijuana

How to start Prescribing

The Texas Compassionate Use Act allows qualified physicians to prescribe low-THC medical cannabis to patients diagnosed with qualifying medical conditions.

Qualified physicians must be board-certified in a medical specialty relevant to the approved medical conditions by a specialty board approved by the American Board of Medical Specialties or the Bureau of Osteopathic Specialists.

The Texas Compassionate Use Program: Register In 4 Easy Steps

Qualifying physicians must register with the Texas Department of Public Safety’s Compassionate Use Registry Portal. The process of registering with the medical cannabis program is straightforward and typically takes less than 10 minutes to apply. To help clarify the process, here’s a quick rundown of how it is done:

The Texas Compassionate Use Act allows qualified physicians to prescribe low-THC cannabis to patients diagnosed with any of the following:

ALS

(Amyotrophic Lateral Sclerosis)

Alzheimer’s Disease

And other dementias

Autism

And other spectrum disorders

Cerebral Palsy

CTE

(Chronic Traumatic Encephalopathy)

Epilepsy

And other seizure disorders

Huntington’s Disease

MS

(Multiple Sclerosis)

Parkinson's Disease

Peripheral Neuropathies

Spasticity

Terminal Cancer

SEE MORE CONDITIONS
  • 3-hydroxy-3-methylglutaryl-CoA lyase deficiency
  • 5-aminoimidazole-4-carboxamide ribonucleotide transformylase deficiency

A

  • Adenylosuccinate synthase Deficiency
  • Alexander disease
  • Alpers-Huttenlocher syndrome
  • Argyrophilic Grain Disease
  • Aromatic L-amino acid decarboxylase deficiency
  • Asparylglucosaminuria
  • Ataxia neuropathy spectrum

B

  • Bidirectional enzyme deficiency
  • Biopterin Defects

C

  • Cerebral Autosomal Dominant Arteriopathy with Sub-cortical Infarcts and Leukoencephalopathy
  • Charcot Marie Tooth and related hereditary neuropathies
  • Childhood Myocerebrohepatopathy spectrum
  • Congenital Disorders of Glycosylation
  • Corticobasal Degeneration
  • Creatine Disorders
  • Creatine Transporter Defect, also known as SLC 6A8
  • Creutzfeldt-Jakob Disease

D

  • Dementia with Lewy Bodies
  • Deoxyguanisine kinase deficiency
  • Dihydropirimidinase Deficiency
  • Dihydropteridine reductase
  • Dihydropyrimidine dehydrogenase Deficiency
  • Duchenne Muscular Dystrophy

F

  • Facioscapulohumeral Muscular Dystrophy
  • Familial or Sporadic Fatal Insomnia
  • Familial Spastic Paraplegia
  • Fatty Acid Oxidation
  • Freidreich’s Ataxia
  • Frontotemporal dementia and parkinsonism linked to chromosome 17 caused by mutations in MAPT gene
  • Frontotemporal Lobar Degeneration

G

  • Galactosialidosis
  • Gaucher Type 2 and Type 3
  • Gerstmann-Straussler-Scheinker Disease
  • Globular Glial Tauopathy
  • Glutaric acidemia type 1
  • Glycine encephalopathy, also known as non-ketotic hyperglycinemia
  • Glycogen Storage-Lysosomal: Pompe Disease
  • GM1 gangliosidosis
  • GM2 gangliosidosis also known as Tay-sachs and Sandhoff Disease
  • Guanidinoacetate methytransferase deficiency
  • Guanosine triphosphate cyclohydrolase deficiency

H

  • Homocysteine re-methylation defects
  • Hypoxanthine-guanine phosophoribosyltransferase Deficiency also known as Lesch-Nyhan disease

K

  • Kearn Sayers Syndrome

L

  • L-2-hydroxyglutaric aciduria
  • L-Arginine/glycine amidinotransferase deficiency
  • Lewy Body Disorders
  • Long-chain L-3 hydroxyacyl-CoA dehydrogenase deficiency
  • Lysosomal Storage Diseases

M

  • Manosidosis alpha and beta
  • Maple Syrup Urine Disease
  • Metachromatic leukodystrophy
  • Metal Metabolism
  • Methylenetetrahydrofolate reductase deficiency severe variant
  • Mitochondrial Conditions
  • Mitochondrial Depletion syndromes types 1 through 14
  • Mitochondrial Encephalopathy Lactic Acidosis Stroke
  • Mitochondrial Encephalopathy Ragged Red Fiber
  • Mitochondrial neurogastrointestinal encephalopathy
  • Monoamine oxidase deficiency
  • Motor Neuron Disease
  • Mucolipidoses Type II, also known as Inclusion Cell disease
  • Mucolipidoses Type III, also known as pseudo-Hurler polydystrophy
  • Mucopolysaccaridosis
  • Mucopolysaccharidosis Type I, also known as Hurler Syndrome or Scheie Syndrome
  • Mucopolysaccharidosis Type II, also known as Hunter Syndrome
  • Mucopolysaccharidosis Type III, also known as Sanfilippo A and B
  • Mucopolysaccharidosis Type IV, also known as Maroteaux-Lamy
  • Mucopolysaccharidosis Type VII, also known as Sly
  • Multiple Sulfatase deficiency
  • Multiple System Atrophy
  • Muscular Dystrophies
  • Myoclonic epilepsy myopathy sensory ataxia

N

  • Neimann Pick Type A and B
  • Neimann Pick Type C
  • Neonatal Adrenoleukodystrophy
  • Neurodegeneration with brain iron accumulation
  • Neurofibrillary Tangle dementia, also known as Primary Age-related Tauopathy
  • Neuronal ceroid lipofuscinosis types 1-10 including Batten Disease
  • Neuropathy, Ataxia, and Retinitis Pigmentosa
  • Neurotransmitter defects

O

  • Oligosaccharidoses

P

  • Pantothenate Kinase Associated Neurodegeneration
  • Pelizaeus-Merzbacher disease
  • Peripheral neuropathy types 1 through 4
  • Peroxisomal biosynthesis defects
  • Peroxisomal Disorders
  • Polymerase G Related Disorders
  • Polyol disorders
  • Primary Lateral Sclerosis
  • Progressive Choreas
  • Progressive dystonias DYT genes 1 through 20
  • Progressive Muscular Atrophy
  • Progressive Supranuclear Palsy
  • Pterin-4-carbinolamine dehydratase
  • Purine and Pyrimidine Defects
  • Pyruvate Carboxylase Deficiency
  • Pyruvate Dehydrogenase Deficiency
  • Pyruvoyl-tetahydropterin synthase

R

  • Respiratory chain disorders complex 1 through 4 defects: Co Q biosynthesis defects
  • RRM2B-related mitochondrial disease

S

  • Segawa Diease, also known as Dopamine Responsive Dystonia
  • Sepiapterin reductase
  • Sphingolipidoses
  • Spinal Muscular Atrophy
  • Spinal-bulbar muscular atrophy
  • Spinocerebellar ataxia
  • Subacute necrotizing encephalopathy, also known as Leigh syndrome
  • SUCLG1-related mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria
  • Synucleinopathies

T

  • Thymidine Kinase
  • Transactive response DNA-binding protein-43 (TDP-43) Proteinopathies
  • Trifunctional protein deficiency

V

  • Vascular dementia

W

X

  • X-linked adrenoleukodystrophy

Z

  • Zellweger syndrome

Prescribing Medical Cannabis In Texas

After your application is approved and you have created your CURT account, you are legally permitted to prescribe low-THC medical cannabis products to patients diagnosed with the aforementioned conditions. Patients must be permanent residents of Texas.

You must determine the potential risks associated with prescribing low-THC cannabis to a patient are reasonable in light of the potential benefits to that patient, and then you can enter your patient & the recommended prescription for low-THC cannabis directly into the Compassionate Use Registry.

In order to enter your patient’s prescription, you’ll need the following:

  • Patient Name, DOB, last 5 SSN (Optional but recommended), address, phone number
  • Recommended dose & frequency
  • Recommended formulation of medicine
  • General treatment plan (all of the treatment plan fields are optional as long as you are capturing this in other records)

Remember that only non-smokable forms of cannabis are approved under the law. Acceptable forms of cannabis ingestion methods include tinctures, sprays, lozenges and other products made from cannabinoids.

It should be noted that a patient can see a CURT-registered physician solely for the purpose of receiving a Cannabis prescription, while retaining their existing relationship with their primary physician.

The patient information you provide to CURT will be stored in a secure online database designed to help enforce patient monitoring and allow law enforcement to identify individuals who are legally allowed to purchase and possess medical cannabis in the state of Texas.

The system is now available to physicians and dispensing organizations 24 hours a day, enabling doctors to be fully prepared for their patients when they are ready to prescribe cannabis-based medicine in Texas.

Have questions or want help from our team?

Registering with the medical cannabis program is understandably new to most physicians, but it’s easy and typically takes only a few minutes. To make the process as easy as possible, reach out to us!

how CAN a medical marijuana prescription help your patients?

Browse a variety of current research and
clinical trials, as well as formulation info
and recommendations, all sorted by state-
approved conditions.

Prescribers and patients can reach Compassionate Cultivation at 512-614-0343.

SUCCESS STORIES

SIGN UP FOR OUR NEWSLETTER

Get updates on our products, qualifying conditions, the medical cannabis industry, and more.